Recruiting

Heat treatment combined with immunotherapy for pancreatic cancer that has spread to the liver

Plain-English translation of NCT06307080 on ClinicalTrials.gov ↗ · Source last updated July 2025 · Translation generated June 2026 · How we translate trials

Read our Pancreatic Cancer research guide →

This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.

What is this trial?

This trial is testing a combination approach for pancreatic cancer that has spread to the liver. The study compares two groups: one receives a heat-based procedure (called multimodal ablation) combined with immunotherapy medication called carreilizumab plus chemotherapy drugs, while the other group receives only the medication combination. The goal is to see if adding the heat treatment improves outcomes.

Pancreatic cancer that spreads to the liver is very difficult to treat, and current standard treatments don't work well enough for many patients. This trial hopes that combining a direct heat-based approach on the tumors with the new immunotherapy medication might help patients live longer and feel better.

Do you qualify?

You likely qualify if…

you are between 18 and 70 years old
you have been newly diagnosed with pancreatic cancer that has spread only to the liver (confirmed by a biopsy or imaging)
your liver tumors are small enough and few enough to safely treat (3 or fewer tumors, each smaller than 3 centimeters)
your overall health is stable enough that your doctor expects you to survive at least 3 months
your liver, heart, lung, and kidney function are acceptable for treatment

You likely don't qualify if…

you have severe liver disease or serious jaundice that makes treatment unsafe
you are pregnant or breastfeeding
you have uncontrolled high blood pressure, diabetes, active infections, or serious heart or lung disease
you have fluid buildup in your abdomen or around your lungs that cannot be controlled
your doctor believes you will likely survive less than 3 months

What participation looks like

If you join this trial, you will be randomly assigned to one of two groups. One group will receive the heat treatment procedure followed by or combined with intravenous medications given every three weeks for 6 weeks total. The other group will receive only the intravenous medications on the same schedule. You will have imaging scans and blood tests to monitor how well the treatment is working and to watch for side effects. The entire active treatment phase lasts about 6 weeks, with follow-up visits afterward.

AI-generated summary from trial data · Jun 9, 2026 · Not medical advice

Trial locations(1 site)

China

Shanghai General Hospital, Shanghai, Shanghai Municipality